Cancer clinical trials in the region Nouvelle-Aquitaine
195 currently recruiting clinical trials
If you are a doctor and would like find matching clinical trials for you patients, create an account or log in
If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial
Phase 2
Lung cancer
#NCT03475953
NSCLC (Non-Small Cell Lung Cancer)
Mesothelium
Non-squamous NSCLC
Locally Advanced
Metastatic
Immunotherapy
Chemotherapy
Targeted therapy
Antibody Drug Conjugates (ADC)
EGFR
ALK
ROS-1
Systemic Treatment-Naive
Institut Bergonié (Bordeaux), Centre Hospitalier Régional Et Universitaire CHRU de Brest (Brest), Institut du cancer de Montpellier (Montpellier), Institut Curie - Paris (Paris), Gustave Roussy (Villejuif) (and 2 more...)
Institut Bergonié
Phase 2
Prostate cancer
#NCT03438552
Adenocarcinoma
Biochemical recurrence
Radiotherapy
Systemic Treatment-Naive
Immunotherapy
Chemotherapy
Car-T
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Centre François Baclesse (Caen ), CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon ), Centre Jean Perrin (Clermont Ferrand ), Institut du cancer de Montpellier (Montpellier), Centre Oscar Lambret (Lille) (and 6 more...)
UNICANCER
Phase 2
Lung cancer
#NCT03093116
NSCLC (Non-Small Cell Lung Cancer)
Metastatic
ROS-1
NTRK-1/2/3
Targeted therapy
Systemic Treatment-Naive
Centre Hospitalier Régional Et Universitaire CHRU de Brest (Brest), CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon ), Centre Hospitalier Universitaire de Grenoble (La Tronche), Centre Antoine Lacassagne (Nice), Centre Hospitalier Universitaire de Poitiers - Site de la Milétrie (Poitiers) (and 3 more...)
Turning Point Therapeutics, Inc.
Phase 2
Lung cancer
#NCT03093116
NSCLC (Non-Small Cell Lung Cancer)
Metastatic
ROS-1
NTRK-1/2/3
Immunotherapy
Chemotherapy
Systemic Treatment-Naive
Targeted therapy
Centre Hospitalier Régional Et Universitaire CHRU de Brest (Brest), CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon ), Centre Hospitalier Universitaire de Grenoble (La Tronche), Centre Antoine Lacassagne (Nice), Centre Hospitalier Universitaire de Poitiers - Site de la Milétrie (Poitiers) (and 3 more...)
Turning Point Therapeutics, Inc.
Phase 2
Colon cancer
Rectal cancer
#NCT03093116
Metastatic
NTRK-1/2/3
Targeted therapy
Systemic Treatment-Naive
Centre Hospitalier Régional Et Universitaire CHRU de Brest (Brest), CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon ), Centre Hospitalier Universitaire de Grenoble (La Tronche), Centre Antoine Lacassagne (Nice), Centre Hospitalier Universitaire de Poitiers - Site de la Milétrie (Poitiers) (and 3 more...)
Turning Point Therapeutics, Inc.
Phase 2
Colon cancer
Rectal cancer
#NCT03093116
Metastatic
NTRK-1/2/3
Immunotherapy
Chemotherapy
Systemic Treatment-Naive
Targeted therapy
Centre Hospitalier Régional Et Universitaire CHRU de Brest (Brest), CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon ), Centre Hospitalier Universitaire de Grenoble (La Tronche), Centre Antoine Lacassagne (Nice), Centre Hospitalier Universitaire de Poitiers - Site de la Milétrie (Poitiers) (and 3 more...)
Turning Point Therapeutics, Inc.
Phase 2
Breast cancer
#NCT02264678
HER2 Negative
HER2 Low
HER2 Positive
Locally Advanced
Metastatic
BRCA 1/2
Systemic Treatment-Naive
Institut Bergonié (Bordeaux), Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain), Centre Léon Bérard (Lyon)
AstraZeneca
Phase 2
Breast cancer
#NCT02264678
HER2 Negative
HR Negative
Locally Advanced
Metastatic
Systemic Treatment-Naive
Institut Bergonié (Bordeaux), Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain), Centre Léon Bérard (Lyon)
AstraZeneca
Phase 2
Colon cancer
Rectal cancer
Anal cancer
#NCT04585750
Locally Advanced
Metastatic
KRAS G12C
KRAS non G12C
Systemic Treatment-Naive
IUCT Oncopôle (Toulouse), Centre Léon Bérard (Lyon), ICANS - Institut de cancérologie Strasbourg Europe (Strasbourg), Gustave Roussy (Villejuif), Institut Bergonié (Bordeaux) (and 2 more...)
PMV Pharmaceuticals, Inc
Phase 2
Lung cancer
#NCT04585750
Locally Advanced
Metastatic
KRAS G12C
KRAS non G12C
Systemic Treatment-Naive
IUCT Oncopôle (Toulouse), Centre Léon Bérard (Lyon), ICANS - Institut de cancérologie Strasbourg Europe (Strasbourg), Gustave Roussy (Villejuif), Institut Bergonié (Bordeaux) (and 2 more...)
PMV Pharmaceuticals, Inc